Alirocumab: Additional Phase III data

Additional data from the double-blind, international Phase III ODYSSEY COMBO II trial in 720 patients with hypercholesterolemia and high cardiovascular risk who were not adequately controlled with lipid-lowering therapy showed that subcutaneous alirocumab every 2 weeks reduced LDL-C from baseline to week 24, the primary endpoint, by 51% vs. 21% for ezetimibe (p<0.0001). At week 52, alirocumab reduced LDL-C from baseline by 50% vs. 18% for ezetimibe (p<0.0001). Data were presented at the European Society of Cardiology meeting in Barcelona. In July, the partners reported that the trial met its primary endpoint (see BioCentury, Aug. 4). ...